Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.

The orphan G-protein-coupled receptor GPR55, which is activated by 1-lysophosphatidylinositol and interacts with cannabinoid (CB) receptor ligands, has been proposed as a new potential drug target for the treatment of diabetes, Parkinson's disease, neuropathic pain, and cancer. We applied β-arrestin assays to identify 3-substituted coumarins as a novel class of antagonists and performed an extensive structure-activity relationship study for GPR55. Selectivity versus the related receptors CB1, CB2, and GPR18 was assessed. Among the 7-unsubstituted coumarins selective, competitive GPR55 antagonists were identified, such as 3-(2-hydroxybenzyl)-5-isopropyl-8-methyl-2H-chromen-2-one (12, PSB-SB-489, IC50 = 1.77 μM, pA2 = 0.547 μM). Derivatives with long alkyl chains in position 7 were potent, possibly allosteric GPR55 antagonists which showed ancillary CB receptor affinity. 7-(1,1-Dimethyloctyl)-5-hydroxy-3-(2-hydroxybenzyl)-2H-chromen-2-one (69, PSB-SB-487, IC50 = 0.113 μM, KB = 0.561 μM) and 7-(1,1-dimethylheptyl)-5-hydroxy-3-(2-hydroxybenzyl)-2H-chromen-2-one (67, PSB-SB-1203, IC50 = 0.261 μM) were the most potent GPR55 antagonists of the present series.

[1]  Yuansong Jiang,et al.  Synthesis of 3-Arylcoumarins Through N-Heterocyclic Carbene Catalyzed Condensation and Annulation of 2-Chloro-2-arylacetaldehydes with Salicylaldehydes. , 2013 .

[2]  M. Abood,et al.  GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. , 2013, Life sciences.

[3]  S. Rees,et al.  Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein–Coupled Receptors , 2013, Journal of biomolecular screening.

[4]  T. Karcz,et al.  Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. , 2013, ACS medicinal chemistry letters.

[5]  M. Storr,et al.  A potential role for GPR55 in gastrointestinal functions , 2012, Current opinion in pharmacology.

[6]  M. Waldhoer,et al.  The Cannabinoid Receptor CB1 Modulates the Signaling Properties of the Lysophosphatidylinositol Receptor GPR55* , 2012, The Journal of Biological Chemistry.

[7]  T. Karcz,et al.  7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. , 2012, Journal of medicinal chemistry.

[8]  Younis Baqi,et al.  Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development. , 2012, Pharmacology & therapeutics.

[9]  K. Varani,et al.  7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists. , 2012, Journal of medicinal chemistry.

[10]  D. McHugh,et al.  Δ9‐Tetrahydrocannabinol and N‐arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC‐1B cells , 2012, British journal of pharmacology.

[11]  Stephen P. H. Alexander.  So what do we call GPR18 now? , 2012, British journal of pharmacology.

[12]  S. Popoff,et al.  The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55 , 2012, Journal of Neuroimmune Pharmacology.

[13]  C. Henstridge.  Off-Target Cannabinoid Effects Mediated by GPR55 , 2012, Pharmacology.

[14]  Yuansong Jiang,et al.  N-Heterocyclic carbene catalyzed conjugate umpolung reactions leading to coumarin derivatives , 2012 .

[15]  J. Moreno-Navarrete,et al.  The l-α-Lysophosphatidylinositol/GPR55 System and Its Potential Role in Human Obesity , 2012, Diabetes.

[16]  A. Irving,et al.  Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids* , 2011, The Journal of Biological Chemistry.

[17]  A. Irving.  New blood brothers: the GPR55 and CB2 partnership , 2011, Cell Research.

[18]  E. Kostenis,et al.  GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils , 2011, Cell Research.

[19]  A. Irving,et al.  Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. , 2011, Molecular endocrinology.

[20]  Y. Obara,et al.  Lysophosphatidylinositol Causes Neurite Retraction via GPR55, G13 and RhoA in PC12 Cells , 2011, PloS one.

[21]  M. Caron,et al.  Screening for Selective Ligands for GPR55 - Antagonists , 2011 .

[22]  R. Ross.  L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. , 2011, Trends in pharmacological sciences.

[23]  T. Yokomizo,et al.  What is the natural ligand of GPR55? , 2011, Journal of biochemistry.

[24]  S. Dowell,et al.  Pharmacology of GPR55 in Yeast and Identification of GSK494581A as a Mixed-Activity Glycine Transporter Subtype 1 Inhibitor and GPR55 Agonist , 2011, Journal of Pharmacology and Experimental Therapeutics.

[25]  R. Piñeiro,et al.  The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation , 2011, Oncogene.

[26]  A. Hohmann,et al.  Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside , 2009, Neurotherapeutics.

[27]  E. Kostenis,et al.  GPR 55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils , 2011 .

[28]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[29]  A. Irving,et al.  GPR55 ligands promote receptor coupling to multiple signalling pathways , 2010, British journal of pharmacology.

[30]  M. Abood,et al.  Pharmacological characterization of GPR55, a putative cannabinoid receptor. , 2010, Pharmacology & therapeutics.

[31]  Z. Vogel,et al.  N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor , 2010, BMC Neuroscience.

[32]  Marc G Caron,et al.  Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands* , 2009, The Journal of Biological Chemistry.

[33]  G. Zaman,et al.  Pharmacological Characterization of Receptor Redistribution and β-Arrestin Recruitment Assays for the Cannabinoid Receptor 1 , 2009, Journal of biomolecular screening.

[34]  C. Müller,et al.  Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. , 2009, Bioorganic & medicinal chemistry.

[35]  A. Irving,et al.  The GPR55 ligand L‐α‐lysophosphatidylinositol promotes RhoA‐dependent Ca2+ signaling and NFAT activation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  A. Yamashita,et al.  2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. , 2008, Journal of biochemistry.

[37]  T. Kenakin.  Allosteric Drug Antagonism , 2009 .

[38]  R. Pertwee.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids , 2005, The AAPS Journal.

[39]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[40]  G. Milligan,et al.  Allosteric modulation of heterodimeric G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.

[41]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[42]  S. Bräse,et al.  Synthesis of 3-Alkylcoumarins from Salicylaldehydes and α,β-Unsaturated Aldehydes Utilizing Nucleophilic Carbenes: A New Umpoled Domino Reaction , 2007 .